(CHICAGO) -- A new cancer drug is being developed in the hopes that it can shrink solid tumors that can form in advanced types of breast, gastric, lung, ovarian, pancreatic, liver and prostate cancers.
Authors of a study testing the drug, found that among advanced cancer patients whose disease did not progress during the study, 69 percent saw their tumors reduce in size by a measurable amount.
But more interestingly, of the 68 patients whose bone metastases could be measured before and after treatment, 59 of them had a partial or complete disappearance of those bone lesions.
Unfortunately, it's not clear how long these effects last since the study only lasted three months.
Another concern is the side effects of the drug. Almost half of the study participants had to have their dosage lowered, while 12 percent had to stop the drug completely due to adverse side effects.
The study's findings will presented in June at the annual meeting for the American Society of Clinical Oncology.
Copyright 2011 ABC News Radio